Taken together, these data show that, in the absence of a functional humoral response using anti-RBD IgG as a proxy, the defects identified in vaccine-induced responses of activated CD4 T cells in patients with MS treated with aCD20 were amplified. Here, CD4 is linked to myeloid sarcoma.